Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
The GLP-1 phenomenon is making the fragmentation and dysfunction of the U.S. health care system even more apparent.
pharmaphorum6d
BMS’ Sotyktu cleared for NHS use in psoriasis
Those include having a Psoriasis Area and Severity Index (PASI ... In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use.
Daily Mail11d
New hope for psoriasis sufferers
A revolutionary new cream has been launched for psoriasis, a condition that causes skin to become red and scaly in patches, which may help thousands of people control the condition properly for ...
pharmaphorum7d
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trial
Jefferies notes that sales upside for bimekizumab are capped in a psoriasis market “dominated ... In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with ...
AOL19d
Ozempic and Wegovy are trimming waistlines—and showing how quickly U.S. health care can turn into a gold rush
arthritis and psoriasis, certain liver diseases, depression, eye disorders, Alzheimer's, and substance use disorders. A recent study even found GLP-1s may reduce the risk of 10 different cancers.